查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595324

药物安全检测市场：按类型、临床试验、特征和最终用户划分 - 2025-2030 年全球预测

Pharmacovigilance Market by Type (Contract Outsourcing, In-house), Clinical Trial (Phase I, Phase II, Phase III), Function, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年药物安全检测市场价值为88.6亿美元，预计到2024年将达到102.4亿美元，复合年增长率为15.80%，到2030年将达到247.6亿美元。

药物安全检测是与检测、评估、理解和预防副作用和其他药物相关问题相关的科学和活动。其范围跨越整个药物生命週期，需要强大的框架来确保病人安全和法规遵循。这包括临床前和临床试验、上市后监测以及对药品市场的主动监测，以尽量减少与药品相关的风险。药物安全检测的使用对于医疗保健提供者、製药公司和监管机构提供及时干预措施以减轻药物不良反应 (ADR) 和提高药物安全性至关重要。医院、药房和研究机构等最终使用部门严重依赖药物安全检测资料来为临床实践和政策决策提供资讯。慢性病盛行率的上升和药物消费的增加正在推动药物安全检测市场的发展。此外，巨量资料分析、人工智慧和机器学习方面的技术进步是实现 ADR 即时资料处理和预测分析的关键成长要素。值得注意的机会包括数位医疗技术和远端医疗的整合，这可以简化资料收集和报告流程。市场挑战包括药物安全检测系统的高成本、区域监管不一致以及整合不同资讯来源资料的复杂性。公司可以透过开发强大的讯号检测系统和预测模型来增强 ADR 识别和分析来进行创新。此外，采用云端基础的解决方案可以提高资料可存取性和安全性，并建立更有效率的报告框架。随着药物安全检测市场自我规范性质的发展，对个人化医疗和以患者为中心的方法的关注提供了重要的成长途径。随着药物安全检测继续满足市场的动态需求并为全球更安全的医疗保健做出贡献，预测药物安全性的生物标记和基因图谱的研究也是一个有前途的创新领域。

主要市场统计
基准年[2023] 88.6亿美元
预测年份 [2024] 102.4亿美元
预测年份 [2030] 247.6亿美元
复合年增长率（%） 15.80%

市场动态：揭示快速发展的药物安全检测市场的关键市场洞察

供需的动态交互作用正在改变药物安全检测市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 慢性病盛行率增加
    • 自愿报告和电子健康记录(EHR) 挖掘中药物安全检测应用的增加
    • 企业对外包服务的需求增加
    • 不良反应和药物毒性发生率增加
  • 市场限制因素
    • 适合小型企业的高成本技术
  • 市场机会
    • COVID-19 的出现带来了新的机会
    • 医疗保健公司增加研发 (R&D) 投资
  • 市场挑战
    • 缺乏技术纯熟劳工

波特五力：驾驭药物安全检测市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解药物安全检测市场的外部影响

外部宏观环境因素在塑造药物安全检测市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解药物安全检测市场的竞争格局

药物安全检测市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵药物安全检测市场供应商的绩效评估

FPNV 定位矩阵是评估药物安全检测市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了药物安全检测市场的成功之路

药物安全检测市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病盛行率增加
      • 自发性通报和电子健康记录 (EHR) 挖掘中药物安全检测应用的增加
      • 玩家对外包服务的需求增加
      • 不良反应和药物毒性发生率增加
    • 抑制因素
      • 适合中小型企业的高成本技术
    • 机会
      • COVID-19 的出现带来了新的机会
      • 医疗保健公司增加研发 (R&D) 投资
    • 任务
      • 缺乏技术纯熟劳工
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章药物安全检测市场：按类型

  • 合约外包
  • 公司内部

第七章 临床试验药物安全检测市场

  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段
  • 临床前

第八章药物安全检测市场：按功能

  • 群组心臟事件记录器
  • 电子病历挖掘
  • 加强 ADR 报告
  • 自愿报告
  • 有针对性的自愿报告

第九章药物安全检测市场：依最终使用者分类

  • 学术研究所
  • 政府机构
  • 健康保险公司
  • 医院和护理提供者
  • 製药和生物技术公司

第十章美洲药物安全检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区药物安全检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲药物安全检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Accenture, PLC
  • Bristol-Myers Squibb Company
  • Capgemini SE
  • ClinChoice
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • HCL Technologies Limited
  • ICON PLC
  • Infosys Limited
  • International Business Machines Corporation
  • IQVIA Inc.
  • ITclinical
  • Laboratory Corporation of America Holdings
  • Linical Co., Ltd.
  • Novartis AG
  • Oracle Corporation
  • Parexel International
  • Pfizer Inc.
  • Quanticate International limited
  • Sanofi SA
  • Syneos Health
  • TAKE Solutions Limited
  • TATA Consultancy Services Limited
  • Wipro Limited
Product Code: MRR-43676CF420A3

The Pharmacovigilance Market was valued at USD 8.86 billion in 2023, expected to reach USD 10.24 billion in 2024, and is projected to grow at a CAGR of 15.80%, to USD 24.76 billion by 2030.

Pharmacovigilance is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. Its scope extends across the entire drug lifecycle, necessitating a strong framework to ensure patient safety and regulatory compliance. This involves preclinical and clinical trials, post-marketing surveillance, and the active monitoring of the pharma market to minimize risks associated with pharmaceuticals. The application of pharmacovigilance is crucial for healthcare providers, pharmaceutical companies, and regulatory bodies, providing timely interventions to mitigate adverse drug reactions (ADRs) and enhance drug safety. End-use sectors, such as hospitals, pharmacies, and research institutions, heavily rely on pharmacovigilance data to inform clinical practices and policy decisions. The rising prevalence of chronic diseases and increased drug consumption propels the pharmacovigilance market. Furthermore, technological advancements in big data analytics, artificial intelligence, and machine learning are crucial growth factors, enabling real-time data processing and predictive analytics for ADRs. Notable opportunities include the integration of digital health technologies and telemedicine, which can streamline data gathering and reporting processes. Challenges in the market include the high cost of pharmacovigilance systems, regulatory discrepancies across regions, and the complex nature of data integration from diverse sources. Companies can innovate by developing robust signal detection systems and predictive models enhancing ADR identification and analysis. Additionally, embracing cloud-based solutions can improve data accessibility and security, fostering more efficient reporting frameworks. As the self-regulatory nature of the pharmacovigilance market evolves, focusing on personalized medicine and patient-centric approaches offers vital paths for growth. Research into biomarkers and genetic profiles to predict drug safety is another promising area of innovation, ensuring that pharmacovigilance continues to meet the dynamic needs of the market and contributes to safer healthcare outcomes globally.

KEY MARKET STATISTICS
Base Year [2023] USD 8.86 billion
Estimated Year [2024] USD 10.24 billion
Forecast Year [2030] USD 24.76 billion
CAGR (%) 15.80%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pharmacovigilance Market

The Pharmacovigilance Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in the Prevalence of Chronic Diseases
    • Rise in Pharmacovigilance Applications in Spontaneous Reporting and Electronic Health Record (EHR) Mining
    • Rise in Demand for Outsourcing Services by Players
    • Rising Incidence of ADR and Drug Toxicity
  • Market Restraints
    • High-cost Technology for Small and Mid-sized Players
  • Market Opportunities
    • Emergence of COVID-19 have Opened New Opportunities
    • Rising Investment in Research and Development (R&D) by Healthcare Companies
  • Market Challenges
    • Lack of Skilled Labor

Porter's Five Forces: A Strategic Tool for Navigating the Pharmacovigilance Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pharmacovigilance Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pharmacovigilance Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pharmacovigilance Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pharmacovigilance Market

A detailed market share analysis in the Pharmacovigilance Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pharmacovigilance Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pharmacovigilance Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pharmacovigilance Market

A strategic analysis of the Pharmacovigilance Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pharmacovigilance Market, highlighting leading vendors and their innovative profiles. These include Accenture, PLC, Bristol-Myers Squibb Company, Capgemini SE, ClinChoice, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, HCL Technologies Limited, ICON PLC, Infosys Limited, International Business Machines Corporation, IQVIA Inc., ITclinical, Laboratory Corporation of America Holdings, Linical Co., Ltd., Novartis AG, Oracle Corporation, Parexel International, Pfizer Inc., Quanticate International limited, Sanofi S.A., Syneos Health, TAKE Solutions Limited, TATA Consultancy Services Limited, and Wipro Limited.

Market Segmentation & Coverage

This research report categorizes the Pharmacovigilance Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Contract Outsourcing and In-house.
  • Based on Clinical Trial, market is studied across Phase I, Phase II, Phase III, Phase IV, and Pre-Clinical.
  • Based on Function, market is studied across Cohort Event Monitoring, EHR Mining, Intensified ADR Reporting, Spontaneous Reporting, and Targeted Spontaneous Reporting.
  • Based on End-User, market is studied across Academic & Research Institutes, Government Agencies, Health Insurance Companies, Hospitals & Care Providers, and Pharma & Biotech Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in the Prevalence of Chronic Diseases
      • 5.1.1.2. Rise in Pharmacovigilance Applications in Spontaneous Reporting and Electronic Health Record (EHR) Mining
      • 5.1.1.3. Rise in Demand for Outsourcing Services by Players
      • 5.1.1.4. Rising Incidence of ADR and Drug Toxicity
    • 5.1.2. Restraints
      • 5.1.2.1. High-cost Technology for Small and Mid-sized Players
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of COVID-19 have Opened New Opportunities
      • 5.1.3.2. Rising Investment in Research and Development (R&D) by Healthcare Companies
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of Skilled Labor
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pharmacovigilance Market, by Type

  • 6.1. Introduction
  • 6.2. Contract Outsourcing
  • 6.3. In-house

7. Pharmacovigilance Market, by Clinical Trial

  • 7.1. Introduction
  • 7.2. Phase I
  • 7.3. Phase II
  • 7.4. Phase III
  • 7.5. Phase IV
  • 7.6. Pre-Clinical

8. Pharmacovigilance Market, by Function

  • 8.1. Introduction
  • 8.2. Cohort Event Monitoring
  • 8.3. EHR Mining
  • 8.4. Intensified ADR Reporting
  • 8.5. Spontaneous Reporting
  • 8.6. Targeted Spontaneous Reporting

9. Pharmacovigilance Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Government Agencies
  • 9.4. Health Insurance Companies
  • 9.5. Hospitals & Care Providers
  • 9.6. Pharma & Biotech Companies

10. Americas Pharmacovigilance Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pharmacovigilance Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pharmacovigilance Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Accenture, PLC
  • 2. Bristol-Myers Squibb Company
  • 3. Capgemini SE
  • 4. ClinChoice
  • 5. F. Hoffmann-La Roche AG
  • 6. GlaxoSmithKline PLC
  • 7. HCL Technologies Limited
  • 8. ICON PLC
  • 9. Infosys Limited
  • 10. International Business Machines Corporation
  • 11. IQVIA Inc.
  • 12. ITclinical
  • 13. Laboratory Corporation of America Holdings
  • 14. Linical Co., Ltd.
  • 15. Novartis AG
  • 16. Oracle Corporation
  • 17. Parexel International
  • 18. Pfizer Inc.
  • 19. Quanticate International limited
  • 20. Sanofi S.A.
  • 21. Syneos Health
  • 22. TAKE Solutions Limited
  • 23. TATA Consultancy Services Limited
  • 24. Wipro Limited

LIST OF FIGURES

  • FIGURE 1. PHARMACOVIGILANCE MARKET RESEARCH PROCESS
  • FIGURE 2. PHARMACOVIGILANCE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PHARMACOVIGILANCE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PHARMACOVIGILANCE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PHARMACOVIGILANCE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PHARMACOVIGILANCE MARKET DYNAMICS
  • TABLE 7. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CONTRACT OUTSOURCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRE-CLINICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COHORT EVENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY EHR MINING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INTENSIFIED ADR REPORTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SPONTANEOUS REPORTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TARGETED SPONTANEOUS REPORTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY HEALTH INSURANCE COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY HOSPITALS & CARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. PHARMACOVIGILANCE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 197. PHARMACOVIGILANCE MARKET, FPNV POSITIONING MATRIX, 2023